1

1 Article

2 **Title**:

- 3 Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors
- 4 of The Cancer Genome Atlas: exploration beyond single-agent therapy
- 5

6 **Authors**:

- 7 Christianne Persenaire, MD¹, Benjamin G. Bitler, PhD^{1,2}, and Bradley R. Corr, MD¹
- 8 1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology,
- 9 University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
- 10 2. Department of Obstetrics & Gynecology, Division of Reproductive Sciences,
- 11 University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
- 12 3. Correspondence: christianne.persenaire@cuanschutz.edu
- 13

14 **Corresponding Author**:

- 15 Christianne Persenaire, MD
- 16 1665 Aurora Court
- 17 Anschutz Cancer Pavilion, 2nd Floor
- 18 Aurora, CO 80045
- 19 Phone: (484) 557-2111
- 20 Email: christianne.persenaire@cuanschutz.edu
- 21
- 22
- 23

2

24 Word Counts:

- 25 Abstract: 199
- 26 Manuscript: 2945

27

28	Simple Summary: Epithelial ovarian cancer can be highly lethal, with limited
29	therapeutic options for patients without BRCA mutations or non-homologous
30	recombination deficient disease. Folate receptor alpha (FR α)-targeting agents have
31	shown promise in the setting of platinum-sensitive and platinum-resistant ovarian
32	cancer, both alone and in combination with available therapies, but the relationship of
33	$FR\alpha$ to other treatment-driving biomarkers is unknown. This study identifies potential
34	targetable mutations in FR α -expressing tumors, including PIK3CA and FGF/R family
35	proteins, and provides a basis for future investigations of novel combinations of $FR\alpha\text{-}$
36	targeting agents with PIK3CA, mTOR, FGF/R, and VEGF inhibitors.
37	
38	Abstract:
39	Epithelial ovarian cancer (EOC) can be highly lethal, with limited therapeutic options for
40	patients with non-homologous recombination deficient (HRD) disease. Folate receptor

41 alpha (FOLR1/FR α)-targeting agents have shown promise both alone and in

42 combination with available therapies, but the relationship of FR α to other treatment-

43 driving biomarkers is unknown. The Cancer Genome Atlas (TCGA) was queried to

44 assess protein and mRNA expression and mutational burden in patients with differential

45 $FR\alpha$ protein-expressing ovarian tumors, and the results referenced against the standard

46 324 mutations currently tested through FoundationOne Companion Diagnostics to

3

47	identify targets of interest. Of 585 samples within TCGA, 121 patients with serous
48	ovarian tumors for whom $FR\alpha$ protein expression was quantified were identified. $FR\alpha$
49	protein expression significantly correlated with FOLR1 mRNA expression (p=7.19x10 ⁻
50	14). Progression free survival (PFS) for the FR α -high group (Q1) was 20.7 months,
51	compared to 16.6 months for the FR α -low group (Q4, Logrank, p=0.886). Overall
52	survival (OS) was 54.1 months versus 36.3 months, respectively; however, this result
53	was not significant (Q1 vs. Q4, Logrank, p=0.200). Mutations more commonly
54	encountered in patients with high FR $lpha$ -expressing tumors included PIK3CA and FGF
55	family proteins. Combinations of FR α -targeting agents with PI3K, mTOR, FGF(R) and
56	VEGF inhibitors warrant investigation to evaluate their therapeutic potential.
57	
58	Keywords: epithelial ovarian cancer, folate receptor alpha, mirvetuximab soravtansine,
59	serous ovarian adenocarcinoma, targeted therapeutics
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	

4

70 **1. Introduction**:

91

71	Ovarian cancer is the second most common gynecologic malignancy affecting women
72	in the United States and accounts for more deaths than all other gynecologic
73	malignancies combined. The standard of care for women with epithelial ovarian cancer
74	(EOC), including ovarian, fallopian tube, and primary peritoneal cancers, remains a
75	combination of cytoreductive surgery and taxane/platinum-based chemotherapies.
76	However, despite advancements in treatment with approved targeted therapies such as
77	poly(ADP-ribose) polymerase (PARP) inhibitors and vascular endothelial growth factor
78	(VEGF) inhibitors, disease recurrence still occurs at an alarming rate of 70-80% [1].
79	Recurrent disease most commonly progresses to a non-curable, platinum-resistant
80	state, and there remains a critical need to develop new therapeutic approaches.
81	
82	Over the past decade, folate and its membrane-bound receptor have garnered
83	increased interest as a potential molecular target, as rapidly dividing cancer cells are
84	highly dependent on folate metabolism for DNA replication [2]. Folate receptor alpha
85	(FOLR1/FR α), specifically, is a transmembrane protein involved in cellular folate
86	transport whose expression is highly restricted in somatic tissues. Approximately 80% of
87	EOC constitutively overexpress this receptor, and elevated expression has been found
88	to be associated with a more aggressive tumor phenotype [3].
89	
90	$FR\alpha\text{-targeting}$ agents range in design from monoclonal antibodies and small molecules

92 fully humanized IgG1 antibody that targets FR α -positive cancer cells, while CT900 is a

to folate-drug and antibody-drug conjugates (ADCs). Farletuzumab, for example, is a

5

93	small molecule thymidylate synthase inhibitor that is transported into tumor cells by its
94	high affinity for the FR α receptor [4]. Vintafolide is a folate-drug conjugate in which a
95	water-soluble folic acid derivative is linked through a peptide spacer to a potent
96	microtubule destabilizing agent called desacetylvinblastine monohydrazide, a vinca
97	alkaloid [4]. Once released within the cell, the vinca alkaloid acts to inhibit the beta-
98	tubulin polymerization necessary for cell division to induce cell cycle arrest.
99	
100	ADCs are a novel class of antineoplastic agents that can utilize FR α as a biomarker-

101 driven target. These entities typically consist of a monoclonal antibody directed against 102 a tumor-associated antigen to which a cytotoxic agent ('payload') is conjugated; once 103 internalized, the payload is released to mediate its cytotoxic effects. This design has the 104 theoretical benefit of minimizing systemic toxicity while maximizing efficacy [5], and the 105 inherent capacity of FR α to internalize large molecules makes the receptor ideally 106 suited for targeting with ADCs such as mirvetuximab soravtansine (MIRV), STRO-002. 107 and MORab-202. Along with farletuzumab, these ADCs, as well as ELU001, a C'Dot 108 drug conjugate (NCT05001282); TPIV200/hu-FR-1, a multi-epitope anti-folate receptor 109 vaccine (NCT02764333) [6]; and ITL-306, a cell-based therapy derived from tumor-110 infiltrating lymphocytes (TIL) whose activity increases when the agent encounters 111 tumor-specific FR α (NCT05397093); are under active investigation.

112

113 MIRV is an ADC with the most clinical evaluation in EOC of its drug class to date. It is 114 comprised of an FR α -binding antibody, cleavable linker, and the maytansinoid DM4, a 115 potent tubulin-targeting agent. Upon antigen binding, the FR α -ADC complex is rapidly

6

internalized and DM4 is released to induce cell cycle arrest and apoptosis. MIRV has the additional benefit of bystander killing, as the cleavable linker design allows active DM4 metabolites to diffuse from the antigen-positive tumor cells into neighboring cells [7]. STRO-002 is another FR α -specific ADC comprised of an anti-FR α human IgG1 antibody, SP8166, conjugated to a cleavable DBCO-3-aminophenyl-hemiasterlin druglinker, while MORab-202 is an ADC in which farletuzumab and eribulin, a microtubule inhibitor, are linked via cleavable cathepsin B [8].

124 Early clinical studies of MIRV in patients with platinum-resistant ovarian cancer (PROC) 125 showed promise, with an objective response rate (ORR) of 39% in a phase lb trial with 126 few grade 3/4 toxicities [9]. In November of 2022, MIRV was granted accelerated 127 approval for FR α positive platinum-resistant ovarian cancer based on results from the 128 SORAYA trial (NCT04296890). Single-agent use in patients with up to three prior lines 129 of therapy, including required bevacizumab, demonstrated an ORR of 32.4%, including 130 five complete responses (CR), and a median duration of response (DOR) of seven 131 months. Response rates were similar regardless of the number of prior therapies 132 received, including PARP inhibitors [10]. More recently, encouraging results from the 133 international phase III randomized controlled trial, MIRASOL, comparing MIRV to 134 investigator's choice chemotherapy (IC) in patients with FR α positive PROC, were 135 presented at the 2023 Annual Meeting of the American Society of Clinical Oncology 136 (ASCO). Study authors found the median overall survival (OS) was 16.5 months with 137 MIRV vs. 12.8 months with IC (HR 0.67, p = 0.0046), while the median progression free 138 survival (PFS) was 5.62 months vs 3.98 months in each respective arm (HR 0.65, p

7

<0.0001). Objective response rate was 42.3% in the MIRV group versus 15.9% in the IC
group (p <0.0001). These findings made MIRV the first treatment to demonstrate a PFS
and OS benefit in PROC compared to IC [11].

142

Other ADCs have had similarly encouraging results. In heavily pretreated patients with advanced EOC, for example, STRO-002 had an ORR of 33% in 33 evaluable patients across all FR α expression levels [12]. A phase I study of MORAb-202 in 22 patients showed a CR, partial response (PR), and stable disease in one, nine, and eight patients, respectively [13].

148

149 Prior efforts to target FR α with farletuzumab and vintafolide were hampered by limited 150 single-agent activity [14, 15]. However, vintafolide showed a statistically significant 151 improvement when used in combination with pegylated liposomal doxorubicin [16], 152 suggesting FR α -targeting agents may prove more effective when used in combination 153 with other agents [17]. Combinatory strategies with other FR α targeting agents are 154 currently under investigation. For example, clinical trials with MIRV in combination with 155 carboplatin (NCT04606914), rucaparib (NCT03552471), bevacizumab (NCT05445778), 156 pegylated liposomal doxorubicin or pembrolizumab (NCT02606305), and gemcitabine 157 (NCT02996825) are underway. Similarly, a study combining STRO-002 with 158 bevacizumab (NCT05200364) is actively recruiting. 159

160 As the relationship of FR α to other treatment-driving biomarkers is currently unknown,

161 the objective of this study was to analyze TCGA to assess protein/mRNA expression

8

- and mutational burden in patients with differential FR α protein-expressing tumors and
- 163 identify potential targets for combination drug therapies.
- 164
- 165 **2. Materials & Methods**:
- 166 The Cancer Genome Atlas (TCGA) Ovarian Serous Cystadenocarcinoma PanCancer
- 167 Atlas was accessed via cBioportal (<u>http://www.cbioportal.org</u>) and queried in May 2022
- 168 to generate a list of patients for whom data regarding tumor levels of FR α protein
- 169 expression were available. Protein expression was calculated based on the Clinical
- 170 Proteomic Tumor Analysis Consortium (CPTAC, Figure 1A) [18].
- 171

172 We stratified patients into quartiles based on FR α expression, where Q1 = FR α high,

173 Q2 = FR α high-intermediate (int.), Q3 = FR α low-int., and Q4 = FR α low. These

- 174 quartiles were used to perform survival analyses and protein expression (Z-score)
- analyses, as well as to examine mRNA expression and gene mutations as a function of
- 176 FR α expression. The results were then referenced against the standard 324 mutations
- 177 currently tested through FoundationOne Companion Diagnostics (CDx), including those
- 178 responsible for microsatellite instability, tumor mutational burden and loss of
- 179 heterozygosity, to identify targets of interest. Statistical analyses were conducted and
- 180 graphs generated in Prism GraphPad (v9.0) using Kaplan Meier curves, as well as
- Logrank, Chi-squared, Spearman's rho, Pearson's rho, Benjamini-Hochberg and
- 182 student t-tests.
- 183

9



185

Figure 1: (A) Consort diagram establishing the TCGA PanCancer Atlas patient
population for whom FRα expression data were available. (B) Columnar scatter plot of
FRα protein expression values by quartile. (C) Columnar scatter plot of FRα mRNA
expression by quartile. (D) Scatter plot depicting Pearson correlation of 0.75 between
FOLR1 mRNA transcription and FRα protein expression. (E) Kaplan Meier curves
depicting overall survival (OS) and progression free survival (PFS) by quartile.

193 **3. Results:**

194 Utilizing TCGA PanCancer Atlas (n=585), we identified 121 patients with serous ovarian

195 tumors for whom FR α protein expression was quantified. Those patients were then

196	stratified into quartiles to assess for correlation with outcomes of interest (Figure 1A-B).
197	TCGA PanCancer Atlas comparison of mRNA expression, protein expression (CPTAC)
198	and genomic alterations was utilized across the four quartiles and data collected for
199	18,695 mRNA transcripts and 7,620 proteins. Both mRNA expression and protein
200	expression of FR $lpha$ decreased in stepwise fashion from Q1 to Q4 (Figure 1B-C), and
201	FOLR1 mRNA expression was significantly elevated (t-test; p=7.19x10 ⁻¹⁴ ; FDR
202	q=6.78x10 ⁻¹⁰) across the different quartiles (Figure 1C). The Pearson correlation
203	between FOLR1 mRNA transcription and FR $lpha$ protein expression was 0.7452
204	(p<0.0001, Figure 1D).
205	
206	When evaluating survival outcomes by quartile, PFS for the FR $lpha$ -high group (Q1) was
207	20.7 months, compared to 16.6 months for the FR $lpha$ -low group (Q1 vs Q4, Logrank,
208	p=0.886). Overall survival was 54.1 months versus 36.3 months, respectively; however,
209	this result was not significant (Q1 vs. Q4, Logrank, p=0.200) (Figure 1E, Table 1).
210	
211	Table 1: Overall survival and progression free survival in patients with EOC stratified by
212	levels of tumor FR α expression; p-values derived by Log Rank test.
	Median Survival in Months

	Q1 (High FOLR1)	Q2 (High Int. FOLR1)	Q3 (Low Int FOLR1)	Q4 (Low FOLR1)	p-value
Overall Survival	54.1	31.3	39.4	36.3	0.2
Months (95% Cl)	(43.2-NA)	(20.9-74.9)	(33.9-NA)	(24.2-70.1)	0.5
Progression Free Survival	20.7	14.5	16	16.6	0.4
Months (95% Cl)	(12.9-27.8)	(11.8-19.6)	(13.0-26.9)	(11.54-NA)	0.4

11

21^{4}	4
----------	---

215	To identify potential molecular targets correlating to FR α expression, data for the 324
216	genes assessed through FoundationOne CDx were collected, as these represent
217	mutations more frequently seen in patients with solid tumors, including EOC, and many
218	represent areas of active investigation for which targeted therapies exist, or are
219	currently in development. From these data, we compiled a list of the top thirty mutations
220	across the FR α quartiles, with results as noted in Table 2. Spearman's rank correlation
221	coefficient was calculated for protein expression for genes part of FoundationOne CDx
222	to identify proteins whose expression was strongly positively or negatively associated
223	with that of FR α protein; these results are shown in Table 3.
224	
225	Table 2 : Most common mutations encountered in tumors with high, high-intermediate,

226 low-intermediate, and low FRα expression; p-values derived by Chi squared test.

		Number of m	utations (%)		
Gene Symbol	Q1 (High FOLR1)	Q2 (High Int. FOLR1)	Q3 (Low Int FOLR1)	Q4 (Low FOLR1)	p-value
PIK3CA	9 (29.03%)	5 (16.67%)	7 (23.33%)	6 (20.69%)	0.703
ETV5	7 (22.58%)	6 (20.00%)	4 (13.33%)	4 (13.79%)	0.724
FGF12	7 (22.58%)	7 (23.33%)	6 (20.00%)	4 (13.79%)	0.793
KLHL6	7 (22.58%)	6 (20.00%)	4 (13.33%)	6 (20.69%)	0.814
RAD21	7 (22.58%)	9 (30.00%)	11 (36.67%)	7 (24.14%)	0.61
CCND1	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
FGF19	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
FGF3	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
FGF4	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
MAP3K13	6 (19.35%)	7 (23.33%)	5 (16.67%)	4 (13.79%)	0.807
SOX2	6 (19.35%)	5 (16.67%)	5 (16.67%)	6 (20.69%)	0.971
IRF4	5 (16.13%)	3 (10.00%)	4 (13.33%)	1 (3.45%)	0.431
TIPARP	5 (16.13%)	3 (10.00%)	4 (13.33%)	3 (10.34%)	0.876
ERBB4	5 (16.13%)	2 (6.67%)	1 (3.33%)	0 (0.00%)	0.0698
ATR	5 (16.13%)	4 (13.33%)	2 (6.67%)	1 (3.45%)	0.332
TERT	4 (12.90%)	3 (10.00%)	2 (6.67%)	0 (0.00%)	0.266
BCL6	4 (12.90%)	6 (20.00%)	4 (13.33%)	5 (17.24%)	0.856
RSPO2	4 (12.90%)	8 (26.67%)	3 (10.00%)	7 (24.14%)	0.257
XRCC2	4 (12.90%)	4 (13.33%)	4 (13.33%)	1 (3.45%)	0.539
BRD4	4 (12.90%)	2 (6.67%)	0 (0.00%)	6 (20.69%)	0.0532
NOTCH3	4 (12.90%)	2 (6.67%)	1 (3.33%)	6 (20.69%)	0.149
SDHA	4 (12.90%)	3 (10.00%)	2 (6.67%)	0 (0.00%)	0.266
CCNE1	4 (12.90%)	4 (13.33%)	5 (16.67%)	7 (24.14%)	0.632
BRAF	4 (12.90%)	5 (16.67%)	3 (10.00%)	4 (13.79%)	0.899
ERBB3	4 (12.90%)	1 (3.33%)	0 (0.00%)	1 (3.45%)	0.113
MCL1	4 (12.90%)	2 (6.67%)	1 (3.33%)	2 (6.90%)	0.552
BRCA1	3 (9.68%)	1 (3.33%)	1 (3.33%)	2 (6.90%)	0.665
BTG2	3 (9.68%)	2 (6.67%)	0 (0.00%)	1 (3.45%)	0.344
CDKN1A	3 (9.68%)	3 (10.00%)	1 (3.33%)	0 (0.00%)	0.27
FOXL2	3 (9.68%)	4 (13.33%)	1 (3.33%)	1 (3.45%)	0.373

13

229 **Table 3**: Proteins with an absolute Spearman's Rho >0.98 suggesting association with

		FOLR1	Protein Ex	pression (Z·	-score)		
Gene Symbol	Gene Name	Q1 (High)	Q2 (High In	Q3 (Low Int	Q4 (Low)	Rho value	p-value
CTNNA1	alpha catenin	0.14	0.03	-0.02	-0.07	0.991	0.002
FH	fumarate hydratase	0.16	0	-0.05	-0.12	0.985	0.013
CDH1	e-cadherin	0.09	0.01	-0.08	-0.21	0.984	0.008
SDHA	succinate dehydrogenase complex flavoprotein subunit A	0.09	0	-0.01	-0.07	0.981	0.110
SRC	proto-oncogene C-Src	-0.08	-0.05	0.01	0.05	-0.977	0.271
АКТ3	protein kinase B, gamma	-0.2	-0.01	0.04	0.12	-0.981	0.529
NF1	neurofibromin 1	-0.09	-0.06	-0.01	0.03	-0.982	0.627
QKI	quaking homolog, KH domain RNA binding	-0.05	0.03	0.07	0.13	-0.999	0.012

230 FOLR1 expression; p-values derived by student's t-test.

231

232

233 Only 160/324 genes on the FoundationOne CDx were identified via CPTAC. Quaking

234 Homolog, KH Domain RNA Binding (QKI) was the most negatively correlated (Pearson r

235 = -0.996) and Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) was

the most positively correlated (Pearson r = 0.993). BRCA1 protein expression was

- 237 undetectable and BRCA2 protein expression did not correlate with FR α protein
- expression (Pearson r = 0.27). Data regarding protein expression for other genes in the
- HRD pathway were available only for ATM, CHEK2 and NBS1, and also showed no
- correlation.

241

242 **4. Discussion:**

243 Targeting FR α is an area of active investigation and one that holds significant promise.

244 In this study, we used TCGA to identify potential molecular targets that could potentiate

14

245 the ORR of FR α -targeting agents and improve their therapeutic efficacy for patients with 246 EOC, particularly those with non-HRD, platinum-resistant disease. We identified an 247 increased frequency of potentially targetable PIK3CA and FGF family protein mutations 248 in FR α -expressing tumors.

249

250 **Results in the Context of Published Literature**:

251 Although early studies of single-agent MIRV, STRO-002, and MORAb-202 suggested 252 these have anti-tumor activity, several combinatorial approaches are under active 253 investigation. MIRV, for example, is being studied in combination with various 254 chemotherapies and targeted therapies such as pembrolizumab and bevacizumab 255 (NCT02606305). In 2018, as part of FORWARD II. Moore et al. published data from the 256 phase 1b escalation study of MIRV in combination with carboplatin in patients with 257 platinum-sensitive ovarian cancer (PSOC), which found a 71% ORR, including three CR 258 and nine PR, and a median PFS of 15 months [19]. Among others, these findings 259 prompted a single arm, phase II trial of carboplatin and MIRV for first-line treatment of 260 patients with advanced, FR α -positive EOC receiving neoadjuvant chemotherapy (NCT04606914). A randomized phase II trial of MIRV in FR α -high, recurrent PSOC 261 262 also began enrolling patients in September 2021, with the goal of comparing platinumbased chemotherapy followed by PARPi (if indicated) to carboplatin + MIRV followed by 263 264 MIRV monotherapy (NCT04274426).

265

For patients with PROC, another expansion cohort from FORWARD II found a
 confirmed ORR of 43% in patients treated with a combination of MIRV and

15

268	pembrolizumab, with a median DOR of 6.9 months and median PFS of 5.2 months [20].
269	The same phase Ib study included a cohort of patients with PROC who received MIRV
270	in combination with bevacizumab; for these patients, the confirmed ORR was 39%,
271	including five CR and 21 PR; median PFS was 6.9 months. Patients who were
272	bevacizumab-naïve, less heavily pretreated, and whose tumors had medium/high $FR\alpha$
273	expression had an ORR of 56% with a median DOR of 12 months and PFS of 9.9
274	months [21]. Given these findings, FORWARD II looked at the combination of MIRV,
275	carboplatin and bevacizumab followed by MIRV and bevacizumab maintenance therapy
276	in 41 patients with recurrent PSOC, with a confirmed ORR of 83%, median DOR of 10.9
277	months and PFS of 12.8 months [22]. These data suggest synergistic and durable anti-
278	tumor effects of combinatorial approaches, and more trials are in active development.
279	
280	In our effort to identify potential targets, we found PIK3CA is mutated in 29% of tumors
281	with high FR α expression. PIK3CA, or phosphatidylinositol-4,-5-bisphosphanate 3-
282	kinase catalytic subunit alpha, is an oncogene that has been implicated in several
283	cancers, including breast, colon, liver, and stomach cancers [23]. Point mutations in this
284	gene can cause hyperactivation of the alpha isoform (p110a) of PI3K, which in turn
285	results in constitutive activation of the intracellular PI3K/Akt signaling pathway. This
286	pathway is linked to several critical physiologic and pathophysiologic functions,
287	including those that drive tumor progression, such as cell proliferation, growth,
288	metabolism, angiogenesis, and motility [24]. Several PI3K inhibitors, such as alpelisib, a
289	small molecule, a-specific PI3K inhibitor that selectively inhibits p110a, are being
290	evaluated, and early work suggests that PIK3CA-mutated cancers are sensitive to

16

treatment with these agents [25]. When given in combination with standard of care
therapies, as with olaparib in ovarian cancer or fulvestrant in breast, these drugs may
work synergistically to overcome tumor resistance and sensitize the tumor cells to
treatment with currently approved agents [26, 27].

295

296 The propensity toward *PIK3CA* mutations in FR α high tumors also provides a basis for 297 investigating combinations of FR α -targeting agents with mammalian target of 298 rapamycin, or mTOR, inhibitors. This is because activation of the PI3K/Akt signaling 299 pathway results in downstream activation of the mTOR pathway. As with the PI3K/Akt 300 pathway, mTOR plays a key role in regulating cell proliferation, and functions as a 301 regulator of autophagy and apoptosis; thus, alterations in this pathway can lead to 302 unchecked cell proliferation. In ovarian cancer, specifically, the PI3K/Akt/mTOR 303 pathway has been found to activated in approximately 70% of cases and has been 304 linked to higher invasive and migratory capacity. The mTOR inhibitors temsirolimus and 305 everolimus have been studied in clinical trials of patients with recurrent EOC and had 306 promising results [28].

307

Importantly, while VEGF was not one of the top mutations identified based on FRα
expression, receptor binding of VEGFR2 has been found to activate PI3K and Akt.
Although the mechanism by which this occurs is not fully understood, it is thought to
occur by TSAd-mediated activation of Src family kinases, which engage the receptor
tyrosine kinase Axl to trigger ligand-independent autophosphorylation and promote
association with PI3K and activation of Akt [29]. This association between VEGFR2 and

17

PI3K/Akt activation, as well as the higher rate of PIK3CA mutations in FRα-high tumors,
may provide a mechanistic basis for the promising therapeutic efficacy seen in the early
trials of patients treated with combinations of MIRV with bevacizumab mentioned
previously. A phase 3 trial to evaluate MIRV in combination with bevacizumab versus
bevacizumab alone in PSOC (GLORIOSA) began recruiting patients in December 2022
(NCT 05445778).

320

321 Other mutations more frequently observed in FR α -high tumors were those of the 322 fibroblast growth factor, or FGF, family, including FGF3 (19.35% vs. 0%), FGF4 323 (19.35% vs. 0%), FGF12 (22.58% vs. 13.79%), and FGF19 (19.35% vs. 0%). Broadly speaking, the fibroblast growth factor receptor (FGFR) family of receptor tyrosine 324 325 kinases consists of four transmembrane receptors, FGFR1-4, and twenty-two known 326 FGF ligands that interact to activate downstream signaling pathways through an 327 intracellular domain. One such pathway is the extracellular signal-regulated kinase 328 (ERK)/mitogen-activated protein kinase (MAPK) pathway, which promotes cell survival, 329 proliferation, angiogenesis, and differentiation-processes exploited in malignant 330 transformation and tumorigenesis [30]. Several agents targeting FGF have been 331 developed for clinical use, ranging from selective tyrosine kinase inhibitors and 332 monoclonal antibodies to ADCs and FGF ligand traps. Two anti-FGFR therapies have 333 been approved by the Food and Drug Administration to date, including erdafitinib for 334 FGFR-3-altered urothelial cancer, and pemigatinib for FGFR-2 fusion 335 cholangiocarcinoma [30]. Lenvatinib, an oral receptor tyrosine kinase inhibitor that has 336 activity against FGFR1-4, as well as VEGFR1-3, platelet derived growth factor receptor-

18

337	beta, and the RET and kit proto-oncogenes, is currently approved for patients with
338	advanced endometrial cancer without microsatellite instability. Given the higher FGF
339	mutation rate seen in FR α -high tumors in this study, investigation into combinations of
340	$FR\alpha$ -targeting therapies with anti-FGF/R modalities may prove a fruitful area of inquiry.
341	
342	It should be noted that the BRCA and HRD pathway genes did not demonstrate a clear
343	correlation with $FR\alpha$ expression. The combinatory strategy with PARP inhibitors was
344	first assessed in NCT03552471 utilizing MIRV and rucaparib in recurrent ovarian,
345	fallopian tube, peritoneal or endometrial cancers. The ORR was 29% in the ovarian
346	cancer cohort with a PFS >6months in 47.1% [31]. The lack of correlation of FR $lpha$
347	expression and BRCA/HRD demonstrates that a synergistic effect between the two is
348	unlikely, but an additive effect in distinct patient populations may warrant future
349	investigation.

350

351 Strengths and Limitations:

352 A pitfall from previous trials was the method of determining FR α expression in primary 353 tumors, which is critical, as subsequent trials observed a strong positive correlation 354 between FR α expression and ORR. One of the strengths of this analysis was the finding 355 that FRa protein expression significantly correlates with FOLR1 mRNA expression. This 356 raises the possibility of examining mRNA expression in lieu of immunohistochemical 357 based assays in future studies. Limitations of this study include those intrinsic to the use 358 of publicly available datasets such as TCGA PanCancer Atlas, which has restricted 359 scope with a limited number of analyzed samples. In this case, data regarding FRa

360	expression were available for only 121 of 585 patients included in the PanCancer Atlas.
361	An additional limitation is the confounding effect of chromosomal locus on the
362	amplification or overexpression of a target of interest. FOLR1 is found on chromosome
363	11; the differential expression of proteins found on chromosome 11 may thus be related
364	to proximity to the FR α gene, resulting in similar transcriptional regulation.
365	
366	5. Conclusion:
367	To date, only a few targetable mutations have been examined as part of combinatorial
368	approaches to the treatment of ovarian cancer; based on our findings, there are multiple
369	avenues for further investigation that have the potential to improve outcomes for
370	patients with advanced EOC who currently lack other therapeutic options. In light of the
371	promising results of MIRASOL, this work provides a compelling indication to explore
372	and/or expand upon potential drug combinations of FR $lpha$ -targeting agents with PI3K,
373	mTOR and FGF/FGFR inhibitors, and bevacizumab to evaluate their therapeutic
374	potential in advanced EOC.
375	
376	Funding:
377	This work was supported in part by the University of Colorado Cancer Center's Shared
378	Resource, funded by NCI grant P30CA046934. This funding did not play a role in study
379	design; collection, analysis, or interpretation of data; writing of the report; or the decision
380	to submit the article for publication.

Author Contributions:

20

- 383 Each author was actively involved in this research and approved the final version for
- 384 submission. The individual contributions are listed below:
- 385 Christianne Persenaire: drafted written manuscript, created figures, and contributed to
- 386 reviews
- 387 Benjamin G. Bitler: conceptual design, drafted written manuscript, created figures, and
- 388 contributed to reviews
- 389 Bradley R. Corr: conceptual design, drafted written manuscript, and contributed to
- 390 reviews
- 391

392 **Conflicts of Interest**:

- 393 Dr. Bitler is funded via unrelated grants from DOD, NIH, ACS, and OCRA. Dr. Corr has
- 394 received honorarium for advisory boards on Merck, AstraZeneca, Novocure, GSK,
- 395 Immunogen, and Imvax. Dr. Corr also receives research funding from Clovis Oncology.
- 396 Dr. Persenaire declares no conflicts of interest.
- 397

398

- 399
- 400
- 401
- 402
- 403
- 404
- 405

21

406 **References**:

- Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian
 cancer. *Ann Oncol.* 2017;28(suppl 8):viii51-viii56. Doi:10.1093/annonc/mdx441
- 409 2. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD. Folate and folate
- 410 receptor alpha antagonists mechanism of action in ovarian cancer. *Gynecol Oncol*.
- 411 2013;131(2):493-498.'
- 412 3. Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer
 413 treatment. *Oncotarget*. 2016;7(32):52553-52574.
- 414 4. Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in

415 oncology. *Nat Rev Clin Oncol*. 2020;17(6):349-359. doi:10.1038/s41571-020-0339-5

- 416 5. Lee EK, Liu JF. Antibody-drug conjugates in gynecologic malignancies. *Gynecol*417 *Oncol.* 2019;153(3):694-702.
- 418 6. Zamarin D, et al; Abstract AP27: A phase 2 study of TPIV200/HUFR-1 (a multi-
- 419 epitope folate receptor alpha vaccine) in combination with durvalumab in patients
- 420 with platinum resistant ovarian cancer. *Clin Cancer Res* 15 November 2019; 25
- 421 (22_Supplement): AP27. <u>https://doi.org/10.1158/1557-3265.OVCASYMP18-AP27</u>
- 422 7. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab
- 423 soravtansine versus chemotherapy in patients with platinum-resistant ovarian
- 424 cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757-765.
- 425 8. Manzano A, Ocaña A. Antibody-Drug Conjugates: A Promising Novel Therapy for
- 426 the Treatment of Ovarian Cancer. *Cancers (Basel)*. 2020;12(8):2223. Published
- 427 2020 Aug 9. Doi:10.3390/cancers12082223

- 428 9. O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase lb study of mirvetuximab
- 429 soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate
- 430 (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian
- 431 cancer. *Gynecol Oncol.* 2020;157(2):379-385.
- 432 10. ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of
- 433 Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting.
- 434 BusinessWire. 19 Mar 2022. Accessed 25 Aug 2022. Online, Available
- 435 https://investor.immunogen.com/news-releases/news-release-details/immunogen-
- 436 presents-full-results-positive-pivotal-soraya-trial> n.pag
- 437 11. Moore KN, Angelergues A, Konecny GE, Banerjee SN, Pignata S, Colombo N, et al.
- 438 Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab
- 439 soravtansine vs. investigator's choice of chemotherapy in platinum-resistant,
- 440 advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers
- 441 with high folate receptor-alpha expression. JCO. 2023 Jun
- 442 10;41(17_suppl):LBA5507–LBA5507.
- 443 12. Naumann RW, Marin LP, Oaknin, A, et al. STRO-002-GM2: A Phase 1 Open-Label,
- 444 Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-
- 445 Folate Receptor Alpha Antibody Drug Conjugate in Combination with Bevacizumab
- in Patients with Advanced Epithelial Ovarian Cancer. Abstract presented at ASCO
- 447 2022 Annual Meeting, Chicago, IL.
- 448 13. Shimizu T, Fujiwara Y, Yonemori K, et al. First-in-Human Phase 1 Study of MORAb-
- 449 202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin

- 450 Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. *Clin*
- 451 *Cancer Res.* 2021;27(14):3905-3915. Doi:10.1158/1078-0432.CCR-20-4740
- 452 14. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized
- 453 monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a
- 454 phase I study. *Clin Cancer Res.* 2010;16(21):5288-5295. doi:10.1158/1078-
- 455 0432.CCR-10-0700
- 456 15. Lorusso PM, Edelman MJ, Bever SL, et al. Phase I study of folate conjugate EC145
- 457 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol. 2012;30(32):4011-
- 458 4016. doi:10.1200/JCO.2011.41.4946
- 459 16. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II
- trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in
- 461 combination versus PLD alone in patients with platinum-resistant ovarian cancer. *J*
- 462 *Clin Oncol* 2013;31:4400-4406.
- 463 17. Ponte JF, Ab O, Lanieri L, et al. Mirvetuximab Soravtansine (IMGN853), a Folate
- 464 Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of
- 465 Standard of Care Therapeutics in Ovarian Cancer Models. *Neoplasia*.
- 466 2016;18(12):775-784. Doi:10.1016/j.neo.2016.11.002
- 467 18. Data used in this publication were generated by the Clinical Proteomic Tumor
- 468 Analysis Consortium (NCI/NIH)
- 19. Moore KN, O'Malley DM, Vergote I, et al. Safety and activity findings from a phase
- 470 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-
- 471 targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients

24

472 with platinum-sensitive ovarian cancer. *Gynecol Oncol.* 2018;151(1):46-52.

- 473 Doi:10.1016/j.ygyno.2018.07.017
- 474 20. Matulonis U, Moore KN, Martin, LP, Vergote IB, Castro C, Gilbert L, Malek K, Birrer
- 475 MJ, O'Malley DM. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-
- 476 targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant
- 477 ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a
- 478 phase lb study. *Abstracts Gynaecological Cancer* 10/2018: Vol 29 Supplement 8,
- 479 VIII339. doi:10.1093/annonc/mdy285.157.
- 480 21. O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab
- 481 soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate
- 482 (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian
- 483 cancer. *Gynecol Oncol.* 2020;157(2):379-385. Doi:10.1016/j.ygyno.2020.01.037
- 484 22. O'Malley DM, Richardson DL, Vergote IB, Gilbert L, Castro C, Provencher D,
- 485 Matulonis UA, Mantia-Smaldone G, Martin L, Zweidler-McKay PA, Moore KN.
- 486 Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FR α)-targeting antibody-
- 487 drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab
- 488 (BEV): Final results from a study in patients with recurrent platinum sensitive ovarian
- 489 cancer. Annals of Oncology (202) 31 (supp_4):S551-S589. DOI:
- 490 10.1016/annonc/annonc276.
- 491 23. Safran M, Rosen N, Twik M, BarShir R, Iny Stein T, Dahary D, Fishilevich S, and
- 492 Lancet D. The GeneCards Suite Chapter, <u>Practical Guide to Life Science</u>
- 493 *Databases* (2022) pp 27-56

- 494 24. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human
- 495 cancers. *Br J Cancer*. 2006;94(4):455-459. doi:10.1038/sj.bjc.6602970
- 496 25. Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in Cancer:
- 497 Clinical Implications and Adverse Effects. Int J Mol Sci. 2021;22(7):3464. Published
- 498 2021 Mar 27. doi:10.3390/ijms22073464
- 499 26. Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K
- 500 inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and
- dose-expansion phase 1b trial. *Lancet Oncol.* 2019;20(4):570-580.
- 502 doi:10.1016/S1470-2045(18)30905-7
- 503 27. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for *PIK3CA*-Mutated, Hormone
- 504 Receptor-Positive Advanced Breast Cancer. *N Engl J Med*. 2019;380(20):1929-
- 505 1940. doi:10.1056/NEJMoa1813904
- 506 28. Gasparri ML, Bardhi E, Ruscito I, et al. PI3K/AKT/mTOR Pathway in Ovarian Cancer
- 507 Treatment: Are We on the Right Track? *Geburtshilfe Frauenheilkd*.
- 508 2017;77(10):1095-1103. doi:10.1055/s-0043-118907
- 509 29. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of
- 510 PI3K/Akt. *EMBO J.* 2012;31(7):1692-1703. doi:10.1038/emboj.2012.21
- 511 30. Krook MA, Reeser JW, Ernst G, et al. Fibroblast growth factor receptors in cancer:
- 512 genetic alterations, diagnostics, therapeutic targets and mechanisms of
- 513 resistance. *Br J Cancer*. 2021;124(5):880-892. doi:10.1038/s41416-020-01157-0
- 514 31. Backes F, Fowler J, Copeland L, Wei L, O'Malley D, Cohn D, Cosgrove C, Hays J,
- 515 Bixel K. Phase I Study of Mirvetuximab Soravtansine (Mirv) and Rucaparib for
- 516 Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

- 517 International Journal of Gynecological Cancer. 2021;31:A13-A4. doi: 10.1136/ijgc-
- 518 2021-IGCS.24. PubMed PMID: WOS:000773625600025.